Trial
NCT05695391
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Collaborators
—
Condition
Hemophilia
Intervention
Coagulation Factor VIIa (Recombinant)
Why stopped
Feasibility considerations - extended timelines to complete recruitment
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-31